Perrigo Biologicals: Controlling shareholder terminates transfer of 21.03% of shares to China Biologics.

Pailin Biotechnology announced that on June 17, 2026, the company received a letter from the controlling shareholder Sheng Bangyinghao regarding the termination of the equity transfer transaction. Due to market fluctuations and changes in the industry environment, Sheng Bangyinghao and China Biotech were unable to complete the delivery procedures within the agreed time, and did not have the objective conditions to continue the transaction. Both parties agreed to terminate the equity transfer transaction of Pailin Biotechnology. The original transaction was intended to transfer 199,878,656 shares, accounting for 21.03% of the total share capital of the company. After the termination of the transaction, the controlling shareholder and the actual controller of the company remain unchanged, and there is no significant adverse impact on the company's independence, governance structure, and production operation.